ライフサイエンスコーパス: DPPIV

1 DPPIV activity was influenced by factors such as age, ve

2 DPPIV binding was lost in swapped FNIII13, -14, and -15

3 DPPIV binding was mediated by the consensus motif T(I/L)

4 DPPIV expression led to a loss of tumorigenicity, anchor

5 DPPIV inhibitors block DPPIV-mediated chemorepulsion.

6 DPPIV is a serine protease present in extracellular flui

7 DPPIV reexpression in prostate cancer cells blocks nucle

8 DPPIV+ donor cells were transplanted 24 hours after HIR

9 DPPIV-positive hepatocytes comprised about half of the D

10 A 1% DPPIV concentration difference between the front and bac

11 ing retrorsine/partial hepatectomy (PH) in a DPPIV- mutant Fischer rat model.

12 In group A, DPPIV(+) hepatocytes were found in the liver.

13 After chronic TAA administration, DPPIV(-) F344 rats exhibited progressive fibrosis, cirrh

14 mas and carcinomas, frequently lose or alter DPPIV cell surface expression.

15 on of the crystal structures of FAPalpha and DPPIV revealed one major difference in the vicinity of t

16 cy and selectivity for POP over FAPalpha and DPPIV.

17 We conclude that seprase, FAPalpha, and DPPIV are related serine integral membrane proteases and

18 es exactly with the appearance of DPPT-L and DPPIV activity in serum-free tissue culture medium.

19 t hepatocyte protein expression patterns and DPPIV enzyme activity in extracts from livers of host ra

20 Seprase and DPPIV form a complex on the cell surface that elicits bo

21 which are non-metalloproteases, seprase and DPPIV, that are responsible for the tissue-invasive phen

22 riments confirmed that anti-megalin and anti-DPPIV antibodies co-precipitate different pools of NHE3.

23 e expression of CD26, through its associated DPPIV enzyme activity, enhanced sensitivity of Jurkat T-

24 onding region in FNIII12, which did not bind DPPIV.

25 DPPIV inhibitors block DPPIV-mediated chemorepulsion.

26 the DPPIV-binding domain of FNIII14 blocked DPPIV/poly-FN adhesion and impeded pulmonary metastasis.

27 BS accompanied by GLP-2 release, enhanced by DPPIV inhibition and inhibited by a GLP-2 receptor antag

28 in substrate recognition by FAP, but not by DPPIV or PREP.

29 Proteolysis by DPPIV may contribute to the in vivo clearance of VPAC2P-

30 ose-dependently increased DBS, unaffected by DPPIV inhibition or by cholecystokinin or 5-HT3 receptor

31 rophil speed and viability are unaffected by DPPIV.

32 The peptidase CD26 (DPPIV/dipeptidylpeptidase IV) removes dipeptides from th

33 CD26/DPPIV has the ability to cleave the chemokine CXCL12/str

34 rocess of CXCL12/SDF-1alpha cleavage by CD26/DPPIV on a subpopulation of CD34(+) cells may represent

35 Finally, inhibiting the endogenous CD26/DPPIV activity on CD34(+) cells enhances the migratory r

36 a potentially useful clinical role for CD26/DPPIV in the treatment of selected human hematological m

37 ty shared with dipeptidyl peptidase IV (CD26/DPPIV).

38 alls, whereas expression of the 105-kDa CD26/DPPIV detected by the mAb 1F7 increases, as does the abi

39 In this paper we show that QPP, like CD26/DPPIV, is synthesized with a propeptide and undergoes N:

40 Unlike the cell surface molecule, CD26/DPPIV, QPP is targeted to intracellular vesicles that ar

41 The target of these inhibitors is not CD26/DPPIV, but probably a novel serine protease, quiescent c

42 The involvement of CD26/DPPIV in CD34(+) hemopoietic stem and progenitor cell mi

43 In addition, we show that expression of CD26/DPPIV is associated with increased phosphorylation of p3

44 ubstrate specificity similar to that of CD26/DPPIV.

45 Until recently, CD26/DPPIV was the only known protease with the ability to cl

46 o future treatment strategies targeting CD26/DPPIV for selected human cancers in the clinical setting

47 We found that CD26/DPPIV is expressed by a subpopulation of CD34(+) hemopoi

48 Inhibition of the CD26/DPPIV peptidase activity may therefore represent an inno

49 In Insall chambers, DPPIV gradients below, similar to, and above the human s

50 sults presented herein associate circulating DPPIV activity with poorer cardiovascular outcomes in hu

51 ncrease of approximately 130% in circulating DPPIV activity compared with healthy subjects.

52 IV (DPPIV)-positive hepatocytes in congeneic DPPIV-deficient rats.

53 tant F344 dipeptidyl peptidase IV-deficient (DPPIV(-)) rats were required for the study.

54 t rat liver was replaced by CMP-FLEC derived DPPIV+ hepatocytes.

55 gnificantly induce oval cells with the donor DPPIV antigen.

56 are anti-targets for the development of DP4 (DPPIV/CD26) inhibitors for treating type II diabetes.

57 nst the related dipeptidyl peptidases (DPPs) DPPIV, DPP9, DPPII, and prolyl oligopeptidase (PREP).

58 ) chimeric livers, which harbored endogenous DPPIV-deficient hepatocytes and transplanted DPPIV-posit

59 The brush border enzymes DPPIV and sucrase-isomaltase still correctly localize at

60 pression vectors were constructed to express DPPIV in human melanoma cells.

61 ibitor monocrotaline, followed by male F344 (DPPIV(+)) bone marrow transplantation.

62 Glu(204) for FAPalpha; Glu(205)-Glu(206) for DPPIV) within the active site of the enzyme.

63 ocytes placed into culture were positive for DPPIV at time zero (after isolation).

64 the SHPC clusters were stained positive for DPPIV in any analyzed samples.

65 ce of the organoid cultures was positive for DPPIV.

66 These data support a potential role for DPPIV in inhibiting NB growth and progression.

67 that together span full-length FN, we found DPPIV-binding sites in type III repeats 13, 14, and 15 (

68 Immunopurified E19 liver cells from DPPIV+ rats were transplanted via splenic injection into

69 from fetal livers or mature hepatocytes from DPPIV(+) F344 rats were transplanted into DPPIV(-) rats

70 Tissues from DPPIV chimeric livers after retrorsine/PH treatment show

71 Fetal liver cells were transplanted from DPPIV(+) F344 rats into DPPIV(-) rats of different ages

72 Furthermore, DPPIV promoted apoptosis, and inhibited SDF1-mediated in

73 ereas the proapoptotic tumor suppressor gene DPPIV/CD26 was down-regulated, followed by an increase i

74 ed from cord blood and that these cells have DPPIV activity.

75 plenic injection into partial hepatectomized DPPIV- rats that had been pretreated with mitomycin C.

76 into the spleen of partially hepatectomized, DPPIV negative (DPPIV-) Fischer host rats exposed to ret

77 LV ablation-induced HF rats displayed higher DPPIV activity in the plasma ( approximately 50%) and he

78 modified by N-terminal acetylation to impart DPPIV resistance.

79 Importantly, DPPIV suppressed the tumorigenic potential of NB cells i

80 nts, liver tissue was harvested and cells in DPPIV+ colonies were phenotyped by immunofluorescence an

81 Extended liver resection was performed in (DPPIV)-deficient F344-Fischer rats.

82 A correlation between the ability to inhibit DPPIV in cell culture and in the human mixed lymphocyte

83 le mechanism of globulin peptides to inhibit DPPIV was through blocking the active dimer formation.

84 t report of the identification of inhibitory DPPIV peptides from amaranth hydrolysates and the predic

85 re transplanted from DPPIV(+) F344 rats into DPPIV(-) rats of different ages (2, 6, 14, or 18 months)

86 l liver cells underwent transplantation into DPPIV(-) mutant F344 rats to follow the fate and differe

87 om DPPIV(+) F344 rats were transplanted into DPPIV(-) rats with thioacetamide (TAA)-induced fibrosis/

88 possibly in cell-mediated immunity involving DPPIV-expressing lymphocytes.

89 into wild-type or dipeptidyl dipeptidase IV (DPPIV) knockout blastocysts.

90 CD26/dipeptidylpeptidase IV (DPPIV) is a membrane-bound extracellular peptidase that

91 eting surface enzyme dipeptidylpeptidase-IV (DPPIV/CD26) as a novel, specific and pathogenetically re

92 in identified it as dipeptidyl peptidase IV (DPPIV) (EC ), which was confirmed by assays of DPPIV enz

93 Dipeptidyl peptidase IV (DPPIV) activity was quantified via fluorometric assay of

94 (F344) rats lacking dipeptidyl peptidase IV (DPPIV) activity with cyclophosphamide (CP).

95 ectopeptidase with dipeptidyl peptidase IV (DPPIV) activity, has an array of diverse functional prop

96 to SHPCs, rats with dipeptidyl peptidase IV (DPPIV) chimeric livers, which harbored endogenous DPPIV-

97 ially its intrinsic dipeptidyl peptidase IV (DPPIV) enzyme activity, results in enhanced topoisomeras

98 the 175-kDa form of dipeptidyl peptidase IV (DPPIV) found in normal human serum is identical with a s

99 s was discovered as dipeptidyl peptidase IV (DPPIV) inhibitors as a potential treatment of diabetes a

100 Dipeptidyl peptidase IV (DPPIV) is a cell surface peptidase expressed by normal m

101 Dipeptidyl peptidase IV (DPPIV) is a serine protease with tumor suppressor functi

102 cell isolates from dipeptidyl peptidase IV (DPPIV) positive (DPPIV+) Fischer donor rats into the spl

103 Dipeptidyl peptidase IV (DPPIV), a cell surface serine protease, inactivates or d

104 hat the activity of dipeptidyl peptidase IV (DPPIV), an enzyme that inactivates peptides that possess

105 splantation marker, dipeptidyl peptidase IV (DPPIV), and GFP.

106 tidases seprase and dipeptidyl peptidase IV (DPPIV), at invadopodia of migratory fibroblasts is a pre

107 ally into syngeneic dipeptidyl peptidase IV (DPPIV)-deficient rats.

108 FAPalpha exhibits a dipeptidyl peptidase IV (DPPIV)-like fold, featuring an alpha/beta-hydrolase doma

109 ng hepatocytes from dipeptidyl peptidase IV (DPPIV)-positive donors into retrorsine-treated DPPIV-neg

110 ent of transplanted dipeptidyl peptidase IV (DPPIV)-positive hepatocytes in congeneic DPPIV-deficient

111 protease related to dipeptidyl peptidase IV (DPPIV).

112 110-kDa subunit of dipeptidyl peptidase IV (DPPIV).

113 the serine protease dipeptidyl peptidase IV (DPPIV).

114 similarity to human dipeptidyl peptidase IV (DPPIV).

115 ly related protease dipeptidyl peptidase IV (DPPIV).

116 digestion, against dipeptidyl peptidase IV (DPPIV); an enzyme known to deactivate incretins, hormone

117 period in syngeneic dipeptidyl peptidase IV (DPPIV-) mutant F344 rats.

118 Lung endothelial dipeptidyl peptidase IV (DPPIV/CD26) is a vascular address for cancer cells decor

119 ed DBS, enhanced by dipeptidyl peptidase-IV (DPPIV) inhibition, at the same time as increasing GLP-2

120 CD26 (dipeptidylpeptidase IV [DPPIV]) is a membrane-bound extracellular peptidase that

121 Wild-type (dipeptidyl peptidase IV [DPPIV(+)]) embryonic day (ED) 14 fetal liver cells under

122 Known DPPIV dipeptides are cleaved by FAPalpha with an approxi

123 Like DPPIV, the gelatinase activity of seprase was completely

124 Ductules bearing the donor hepatocyte marker DPPIV were seen at 30 days after bile duct ligation.

125 cell population expressed both donor marker (DPPIV) and alpha-fetoprotein, and some differentiated in

126 formation in melanocytes, SPRIGHTLY-mediated DPPIV down-regulation may play an important role in mela

127 ell death were achieved by blocking membrane DPPIV and cytosolic DPP8 and DPP9.

128 Reexpression of either wild-type or mutant DPPIV rescued expression of a second putative cell surfa

129 ine protease activity, assessed using mutant DPPIV molecules containing serine-->alanine substitution

130 ed syngeneic dipeptidyl peptidase IV mutant (DPPIV(-)) F344 rats.

131 of partially hepatectomized, DPPIV negative (DPPIV-) Fischer host rats exposed to retrorsine.

132 also evaluated the distribution of the NHE3-DPPIV complex in microdomains of rabbit renal brush bord

133 ed pits) in which NHE3 is inactive, the NHE3-DPPIV complex was predominantly in the microvillar fract

134 Moreover, FAPalpha, but not DPPIV, possesses endopeptidase activity toward N-termina

135 Oropharyngeal aspiration of DPPIV inhibits the bleomycin-induced accumulation of mou

136 PIV) (EC ), which was confirmed by assays of DPPIV enzyme activity.

137 n to create hybrid livers in which clones of DPPIV hepatocytes colonize variable portions of the lobu

138 ntation of ED 14 FLEP cells, new clusters of DPPIV+ cells appeared after 4 to 6 months, suggesting re

139 ophils away from the higher concentration of DPPIV.

140 Antibodies to the gelatin-binding domain of DPPIV reduce the cellular abilities of the proteases to

141 ults support the view that downregulation of DPPIV is an important early event in the pathogenesis of

142 The highest inhibition of DPPIV was observed with amaranth peptides released after

143 Loss of DPPIV expression occurs during melanoma progression at a

144 Measurements of DPPIV activity in blood samples obtained from 190 patien

145 The therapeutic potential of DPPIV inhibition in preventing cardiac dysfunction is al

146 Because down-regulation of DPPIV is known to be associated with malignant transform

147 The release of DPPIV was generally greater from CD4+ cells than from CD

148 g a covalent bond with the serine residue of DPPIV.

149 Restoration of DPPIV expression in NB cells led to their differentiatio

150 Silencing of DPPIV by small interfering RNA resulted in increased bFG

151 ese inhibitors bind to the catalytic site of DPPIV with the cyano group forming a covalent bond with

152 mined the effect of binding site peptides on DPPIV/poly-FN adhesion and metastasis.

153 Since the only DPPIV cells inoculated in the cultures were hepatocytes,

154 toward DPP8 (147 nM) and DPP9 (170 nM) over DPPIV (200 muM).

155 ike the closely related dipeptidyl peptidase DPPIV, the extracellular domain of FAP can be released i

156 orrelations were observed between the plasma DPPIV activity and LV end-diastolic pressure and lung co

157 om dipeptidyl peptidase IV (DPPIV) positive (DPPIV+) Fischer donor rats into the spleen of partially

158 es this activity, we identified two putative DPPIV homologs (HcDPPIVA and HcDPPIVB) in H. capsulatum

159 In young adult rats, DPPIV inhibition resulted in an increase in NPY overflow

160 n vivo system remains that of the recipient (DPPIV negative) rat.

161 ice and visualized in chimeras as bright red DPPIV-positive cells in the DPPIV knockout chimeric mice

162 Reexpressing DPPIV in melanoma cells at or below levels expressed by

163 The T cell-released DPPIV is able to function as a costimulating molecule fo

164 atory function, suggesting that the released DPPIV may serve an important immunoregulatory function i

165 rganoid cultures, we utilized the retrorsine/DPPIV system of hepatocyte transplantation to create hyb

166 Furthermore, expression of the seprase-DPPIV complex is restricted to migratory cells involved

167 at which recombinant soluble CD26 and serum DPPIV exhibit costimulatory function, suggesting that th

168 verse correlation was observed between serum DPPIV activity and left ventricular (LV) ejection fracti

169 below, similar to, and above the human serum DPPIV concentration cause movement of human neutrophils

170 ted Thy-1(+) cells produced only rare, small DPPIV(+) cell clusters, very few of which exhibited a he

171 trate that the addition of exogenous soluble DPPIV enhanced sensitivity of lymphoid tumor cell lines

172 over, the results demonstrate that long-term DPPIV inhibition mitigates the development and progressi

173 These results indicate that DPPIV functions as a chemorepellent of human and mouse n

174 These results indicate that DPPIV inhibits the malignant phenotype of prostate cance

175 Our studies show that DPPIV is expressed in normal neural crest-derived struct

176 dy, using in vitro model system we show that DPPIV loss is associated with increased bFGF production

177 The present data suggest that DPPIV plays a significant role in modulating the actions

178 Peptides containing the DPPIV-binding domain of FNIII14 blocked DPPIV/poly-FN ad

179 atocytes are the only cells positive for the DPPIV marker enzyme in the hybrid livers.

180 lating in the serum and is distinct from the DPPIV activity of 105-kDa CD26.

181 Here, we identified the DPPIV-binding sites in FN and examined the effect of bin

182 as as bright red DPPIV-positive cells in the DPPIV knockout chimeric mice.

183 tive hepatocytes comprised about half of the DPPIV chimeric liver mass.

184 zation of the functional implications of the DPPIV/poly-FN adhesion in metastasis and possibly in cel

185 We show that the DPPIV released from activated T cells is antigenically,

186 blation-induced HF rats was treated with the DPPIV inhibitor sitagliptin (40 mg/kg BID) for 6 weeks,

187 ctive and potent VPAC2 agonist, resistant to DPPIV proteolysis, and exhibits substantially improved h

188 biochemically, and enzymatically similar to DPPIV circulating in the serum and is distinct from the

189 ane proteases and that seprase is similar to DPPIV, the proteolytic activities of which are dependent

190 One month after transplantation, DPPIV(+) FLEC engrafted into the parenchyma exhibited an

191 DPPIV-deficient hepatocytes and transplanted DPPIV-positive hepatocytes, were subjected to retrorsine

192 PIV)-positive donors into retrorsine-treated DPPIV-negative recipients subjected to partial hepatecto

193 raise the possibility that association with DPPIV may affect NHE3 surface expression and/or activity

194 crease in catalytic efficiency compared with DPPIV.

195 ein alpha, which can form a heterodimer with DPPIV.

196 atocytes followed by their localization with DPPIV histochemistry showed 3- to 5-fold increases in th

197 ilico prediction of their binding modes with DPPIV.

198 ed rats had no increase in NPY overflow with DPPIV inhibition (P <0.05).